View Clinical Trial (Medical Research Study)
Neuroimaging Studies of Reward Processing in Depression
| City: |
|
Boston |
| State: |
|
Massachusetts |
| Zip Code: |
|
02114 |
| Conditions: |
|
Depression |
| Purpose: |
|
This study will examine brain responses associated with reinforcement and reward tasks in
individuals with major depressive disorder (MDD).
|
| Study Summary: |
|
Major depressive disorder (MDD) is a severe form of depression that can significantly
interfere with an individual's thoughts, behavior, mood, and physical health. People who
suffer from MDD may experience anhedonia, or the inability to gain pleasure from normally
pleasurable experiences. Such individuals do not respond to motivational rewards in the same
way as do individuals who are not depressed. Anhedonia has been recognized as a core symptom
of depression and it is not always remedied with antidepressant medication. Abnormal brain
activity and processing may be the underlying cause of depression and specifically
anhedonia. A better understanding of the brain mechanisms of depression may lead to the
development of new effective medications or psychological treatments.
Event-related potential (ERP), which measures electrical activity in the brain, and
functional magnetic resonance imaging (fMRI), which uses scanned images to illustrate
changes in brain activity, are two techniques that can identify abnormal areas of brain
processing. The purpose of this study is to use ERP and fMRI to compare brain activity that
is related to reward processing in individuals with MDD versus individuals without MDD.
This study will consist of 3 study visits; visits will be scheduled as close together as
possible. At the first study visit, potential participants will be assessed with the SCID
(Structured Clinical Interview for DSM-IV), which will identify individuals with the
diagnostic criteria for MDD. A control group of non-depressed individuals will also be
enrolled in the study. During the second and third study visits, participants will take part
in a monetary reinforcement reward task followed by a signal detection reward task. Brain
activity of all participants will be monitored during both tasks. During the second study
visit, ERP will be used; during the third study visit, fMRI will be used. Demographic
information will also be collected, and participants will complete several standardized
questionnaires to assess mood. Some participants will be asked to return after eight weeks
to complete the fMRI and EEG sessions again. Those who do complete all five sessions will be
awarded a bonus.
|
| Criteria: |
|
Overall Inclusion Criteria:
- Right-handed
- Agrees to use an effective form of contraception throughout the study
Inclusion Criteria for Depressed Participants:
- Meets overall inclusion criteria
- Meets DSM-IV diagnosis criteria for major depressive disorder
- Score of at least 16 on the 21-item HAM-D scale
Overall Exclusion Criteria:
- Left-handed or ambidextrous
- Claustrophobic
- Neurological or medical illness (e.g., attention deficit hyperactivity disorder, head
injury, loss of consciousness, seizures)
- Pregnant
Exclusion Criteria for Depressed Participants:
- Meets any of the overall exclusion criteria
- Has been treated with electroconvulsive therapy within 6 months of study entry
- Has taken any benzodiazepine medications for at least 2 weeks prior to study entry
and discontinued use of the medication for reasons other than participating in the
study
- Has taken any dopaminergic medications (including methylphenidate) or neuroleptics
for at least 6 months prior to study entry and discontinued use of the medication for
reasons other than participating in the study
- Has taken any fluoxetine medications for at least 6 weeks prior to study entry and
discontinued use of the medication for reasons other than participating in the study
- Has taken any medications that may have antidepressant properties (including some
herbal supplements) within 2 weeks of study entry
- Has taken any medications that may affect blood flow (including some blood pressure
medications) within 2 weeks of study entry
- Current or past history of MDD with psychotic features
- Meets DSM-IV diagnosis criteria for organic mental disorder; substance use disorder
(within 1 year of study entry); lifetime substance dependence; schizophrenia;
delusional disorder; bipolar disorder; post-traumatic stress disorder; eating
disorder; acute bereavement; severe borderline or antisocial personality disorder; or
any psychotic disorder not otherwise specified
- Current primary diagnosis of panic disorder, social phobia, generalized anxiety
disorder, obsessive-compulsive disorder, or somatoform disorder
Exclusion Criteria for Control Participants
- Meets any of the overall exclusion criteria
- Diagnosed with any medical or neurological illness
- Diagnosed with any current or past psychiatric illness, as assessed by the SCID-I,
including substance abuse or dependence (e.g., alcohol)
- Has taken any medications that may have antidepressant properties (including some
herbal supplements) within 2 weeks of study entry
- Has taken any psychotropic medications within 2 weeks of study entry
- Has taken any medications that may affect blood flow (including some blood pressure
medications) within 2 weeks of study entry
Exclusion Criteria for fMRI Studies:
- Meets any of the overall exclusion criteria
- Fails to meet safety standards for fMRI
- Current back problems
- Has strongly corrected vision, but does not wear contact lenses
- Weighs more than 250 pounds or exceeds the limit of height-to-weight ratio for a
comfortable fit in the scanner
- Pregnant
- Current alcohol or substance abuse
- At risk for suicide or homicide
|
| NCT ID: |
|
NCT00183755 |
| Primary Contact: |
|
Principal Investigator
Diego A. Pizzagalli, PhD
Harvard University
Diego A. Pizzagalli, PhD
Phone: 617-496-8896
Email: dap@wjh.harvard.edu
|
| Backup Contact: |
|
Email: sdutra@wjh.harvard.edu
Sunny J. Dutra, BA
Phone: 617-384-9841
|
| Location Contact: |
|
Boston, Massachusetts 02114
United States
Adrienne Van Nieuwenhuizen, BA
Phone: 617-724-3222
Email: avannieuwenhuizen@partners.org
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|